Northern Trust’s Mirum Pharmaceuticals MIRM Stock Holding History

Northern Trust’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52.9M	Buy	452,036 +57,116	+14%	+$5.73M	0.01%	1165
2026 Q1	$36.5M	Buy	394,920 +20,056	+5%	+$1.89M	﹤0.01%	1310
2025 Q4	$29.6M	Sell	374,864 -10,472	-3%	-$752K	﹤0.01%	1419
2025 Q3	$28.2M	Sell	385,336 -17,060	-4%	-$1.08M	﹤0.01%	1469
2025 Q2	$20.5M	Buy	402,396 +13,475	+3%	+$600K	﹤0.01%	1632
2025 Q1	$17.5M	Sell	388,921 -10,623	-3%	-$501K	﹤0.01%	1704
2024 Q4	$16.5M	Buy	399,544 +32,059	+9%	+$1.34M	﹤0.01%	1819
2024 Q3	$14.3M	Buy	367,485 +90,119	+32%	+$3.59M	﹤0.01%	1842
2024 Q2	$9.48M	Sell	277,366 -3,713	-1%	-$97.3K	﹤0.01%	2030
2024 Q1	$7.06M	Sell	281,079 -6,956	-2%	-$191K	﹤0.01%	2272
2023 Q4	$8.5M	Buy	288,035 +12,801	+5%	+$387K	﹤0.01%	2172
2023 Q3	$8.7M	Buy	275,234 +1,375	+0.5%	+$37.7K	﹤0.01%	2103
2023 Q2	$7.08M	Buy	273,859 +59,662	+28%	+$1.59M	﹤0.01%	2293
2023 Q1	$5.15M	Buy	214,197 +1,512	+0.7%	+$34.5K	﹤0.01%	2455
2022 Q4	$4.15M	Buy	212,685 +4,523	+2%	+$89.4K	﹤0.01%	2599
2022 Q3	$4.37M	Buy	208,162 +31,396	+18%	+$756K	﹤0.01%	2573
2022 Q2	$3.44M	Buy	176,766 +90,439	+105%	+$2.13M	﹤0.01%	2749
2022 Q1	$1.9M	Sell	86,327 -2,908	-3%	-$59.3K	﹤0.01%	3130
2021 Q4	$1.42M	Buy	89,235 +490	+0.6%	+$7.62K	﹤0.01%	3399
2021 Q3	$1.77M	Sell	88,745 -7,233	-8%	-$118K	﹤0.01%	3350
2021 Q2	$1.66M	Sell	95,978 -957	-1%	-$17.1K	﹤0.01%	3405
2021 Q1	$1.92M	Sell	96,935 -1,399	-1%	-$26.8K	﹤0.01%	3266
2020 Q4	$1.72M	Sell	98,334 -2,655	-3%	-$52.2K	﹤0.01%	3268
2020 Q3	$1.95M	Buy	100,989 +635	+0.6%	+$13.6K	﹤0.01%	3077
2020 Q2	$1.95M	Buy	100,354 +30,448	+44%	+$509K	﹤0.01%	3055
2020 Q1	$978K	Buy	69,906 +23,294	+50%	+$382K	﹤0.01%	3231
2019 Q4	$1.14M	Buy	46,612 +9,799	+27%	+$104K	﹤0.01%	3354
2019 Q3	$370K	Buy	+36,813	New	+$452K	﹤0.01%	3616

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust's MIRM Position: Q2 2026 in Review

Northern Trust increased its Mirum Pharmaceuticals (MIRM) stake by 14% in Q2 2026, buying an estimated $5.73M and bringing the position to 452,036 shares worth $52.9M. The position accounts for 0.01% of the portfolio, ranked #1165.

Northern Trust first reported a position in MIRM in Q3 2019 and has held it in 28 quarters since. 328 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Northern Trust held 452,036 shares of Mirum Pharmaceuticals worth $52.9M as of Q2 2026.
Northern Trust bought 57,116 Mirum Pharmaceuticals shares in Q2 2026, an estimated $5.73M.
Mirum Pharmaceuticals made up 0.01% of Northern Trust's portfolio in Q2 2026, its #1165 holding.
Northern Trust first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 28 quarters since.
328 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.